SCHEMBL5074482

SCHEMBL5074482

Cc1cc(OOP(C)(=O)O)cc(C)c1Cc1ccc(O)c(C(C)C)c1

nearest known ligand 0.73

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
THRB P10828 20/20 0.73
THRA P10827 19/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1458026 0.93 THRB (0.77) THRBTHRA
SCHEMBL3157677 0.88 THRB (0.73) THRBTHRA
SCHEMBL3160842 0.86 THRB (0.85) THRBTHRA
Mb07344 SCHEMBL282003 0.85 THRB (1.00) THRBTHRA
Mb07344 SCHEMBL29378732 0.85 THRB (1.00) THRBTHRA
SCHEMBL13703175 0.85 THRB (0.83) THRBTHRA
SCHEMBL282183 0.84 THRB (0.71) THRBTHRA
SCHEMBL1458111 0.84 THRB (0.74) THRBTHRA
SCHEMBL13946891 0.84 THRB (0.87) THRBTHRA
SCHEMBL282795 0.84 THRB (1.00) THRBTHRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230372275-A1 Compositions and Methods of Treating or Preventing Fibrotic Lung Diseases UNIV YALE (US) 2023-11-23 US claimed
US-20230364044-A1 Methods of Treating or Preventing Acute Respiratory Distress Syndrome THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 2023-11-16 US claimed
EP-3644983-B1 COMPOSITIONS AND METHODS OF TREATING OR PREVENTING FIBROTIC LUNG DISEASES UNIV YALE (US) 2023-10-25 EP claimed
EP-3765059-A1 METHODS OF TREATING OR PREVENTING ACUTE RESPIRATORY DISTRESS SYNDROME Yale University (US) 2021-01-20 EP claimed
US-20210008020-A1 Methods of Treating or Preventing Acute Respiratory Distress Syndrome THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 2021-01-14 US claimed
EP-3644983-A1 COMPOSITIONS AND METHODS OF TREATING OR PREVENTING FIBROTIC LUNG DISEASES Yale University (US) 2020-05-06 EP claimed
US-20200113863-A1 Compositions and Methods of Treating or Preventing Fibrotic Lung Diseases YALE UNIVERSITY 2020-04-16 US claimed
WO-2019178023-A1 Methods of Treating or Preventing Acute Respiratory Distress Syndrome YALE UNIVERSITY (US) 2019-09-19 WO claimed
WO-2019005816-A1 COMPOSITIONS AND METHODS OF TREATING OR PREVENTING FIBROTIC LUNG DISEASES YALE UNIVERSITY (US) 2019-01-03 WO claimed
US-20230372275-A1 Compositions and Methods of Treating or Preventing Fibrotic Lung Diseases UNIV YALE (US) 2023-11-23 US disclosed
US-20230364044-A1 Methods of Treating or Preventing Acute Respiratory Distress Syndrome THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 2023-11-16 US disclosed
EP-3644983-B1 COMPOSITIONS AND METHODS OF TREATING OR PREVENTING FIBROTIC LUNG DISEASES UNIV YALE (US) 2023-10-25 EP disclosed
US-11660281-B2 Compositions and methods of treating or preventing fibrotic lung diseases YALE UNIVERSITY (US) 2023-05-30 US disclosed
EP-3765059-A1 METHODS OF TREATING OR PREVENTING ACUTE RESPIRATORY DISTRESS SYNDROME Yale University (US) 2021-01-20 EP disclosed
EP-3644983-A1 COMPOSITIONS AND METHODS OF TREATING OR PREVENTING FIBROTIC LUNG DISEASES Yale University (US) 2020-05-06 EP disclosed
US-20200113863-A1 Compositions and Methods of Treating or Preventing Fibrotic Lung Diseases YALE UNIVERSITY 2020-04-16 US disclosed
WO-2019178023-A1 Methods of Treating or Preventing Acute Respiratory Distress Syndrome YALE UNIVERSITY (US) 2019-09-19 WO disclosed
WO-2019005816-A1 COMPOSITIONS AND METHODS OF TREATING OR PREVENTING FIBROTIC LUNG DISEASES YALE UNIVERSITY (US) 2019-01-03 WO disclosed
EP-1891080-A2 NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS Metabasis Therapeutics, Inc. (US) 2008-02-27 EP disclosed
WO-2006128055-A2 NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS METABASIS THERAPEUTICS, INC. (US) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210008020-A1 Methods of Treating or Preventing Acute Respiratory Distress Syndrome TSHR, ADRB3, TRHR THRB 6/4885THRA 4/4885
US-20230372275-A1 Compositions and Methods of Treating or Preventing Fibrotic Lung Diseases ADRB3, ADRB1, TGFBR2 THRB 6/4885THRA 13/4885
US-11660281-B2 Compositions and methods of treating or preventing fibrotic lung diseases ADRB3, ADRB1, TGFBR1 THRB 5/4885THRA 8/4885
US-20230364044-A1 Methods of Treating or Preventing Acute Respiratory Distress Syndrome TSHR, ADRB3, TRHR THRB 6/4885THRA 4/4885
US-20200113863-A1 Compositions and Methods of Treating or Preventing Fibrotic Lung Diseases ADRB3, ADRB1, TGFBR1 THRB 5/4885THRA 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.